Halozyme Therapeutics Inc HALO:NASDAQ

Set Alert Options Streaming Charts

Last Price$44.48NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change+0.48(1.09%)

Bid (Size)$42.10 (3)

Ask (Size)$46.85 (8)

Day Low / High$43.46 - 44.64

Volume1.1 M

Chart Style Historical Chart Icon

Historical Chart Icon

Download historical data

View Biotechnology IndustryPeer Comparison as of 07/01/2022

Halozyme Therapeutics Inc ( NASDAQ )

Price: $44.48

Change: +0.48 (1.09%)

Volume: 1.1 M

4:00PM ET 7/01/2022

Detailed Quote|Set Alert|Options Chain

N/A ( N/A )

Price: N/A

Change: N/A N/A

Volume: N/A

N/A

Detailed Quote|Set Alert|Options Chain

Exelixis Inc ( NASDAQ )

Price: $21.57

Change: +0.75 (3.60%)

Volume: 2.1 M

4:00PM ET 7/01/2022

Detailed Quote|Set Alert|Options Chain

Exact Sciences Corp ( NASDAQ )

Price: $41.13

Change: +1.74 (4.42%)

Volume: 1.5 M

4:00PM ET 7/01/2022

Detailed Quote|Set Alert|Options Chain

Novavax Inc ( NASDAQ )

Price: $57.15

Change: +5.72 (11.12%)

Volume: 6.4 M

4:00PM ET 7/01/2022

Detailed Quote|Set Alert|Options Chain

Read more news Recent News

--Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare, Industrial Tech, and Software Sectors

8:40AM ET 7/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Halozyme Therapeutics Launches Testosterone Replacement Therapy Drug Tlando

10:49AM ET 6/07/2022 MT Newswires

Halozyme Therapeutics (HALO) said Tuesday it has commercially launched Tlando, an oral treatment for testosterone replacement therapy in adult males for...

Goldman Sachs Raises Halozyme Therapeutics' Price Target to $60 From $48, Buy Rating Kept

10:37AM ET 5/26/2022 MT Newswires

Halozyme Therapeutics (HALO) has an average rating of outperform and price targets ranging from $19 to $62, according to analysts polled by Capital IQ. (MT...

Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition

9:47AM ET 5/12/2022 MT Newswires

Halozyme Therapeutics (HALO) said Thursday the waiting period under the Hart-Scott-Rodino antitrust act for its planned acquisition of Antares Pharma has...

View all Commentary and Analysis

Merger Arbitrage Mondays: Broadcom To Acquire VMware For $69 Billion

10:19AM ET 5/30/2022 Seeking Alpha

Halozyme: Antares Pharma Bolsters Growth Prospects

5:41AM ET 5/19/2022 Seeking Alpha

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2022 Results - Earnings Call Transcript

10:14PM ET 5/10/2022 Seeking Alpha

Halozyme Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

5:01PM ET 5/10/2022 Seeking Alpha

Company Profile

Business Description

Number of Employees	281

Recent SEC Filing	05/24/2022 SC TO-T/A

Company Highlights

Price Open	$44.03
Previous Close	$44.00
52 Week Range	$31.36 - 48.58
Market Capitalization	$6.1 B
Shares Outstanding	137.9 M
Sector	Health Technology
Industry	Biotechnology
Next Earnings Announcement	08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings	14.88
Earnings per Share	$2.98
Beta vs. S&P 500	N/A
Revenue	$151.9 M
Net Profit Margin	92.23%
Return on Equity	202.61%

Analyst Ratings as of 06/30/2022

Buy	5
Overweight	0
Hold	1
Underweight	0
Sell	1
Consensus Recommendation

Powered by Factset

Click Here